Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab

JOURNAL OF HEPATOLOGY

卷:51

Article

Sanchez, Mayra J.¹  Buti, Maria¹  Homs, Maria²  Palacios, Andres³  Rodriguez-Frias, Francisco²  Esteban, Rafael¹ 

[1] Hosp Valle De Hebron, Liver Unit, CIBERehd Inst Carlos III, Barcelona 08035, Spain

[2] Hosp Valle De Hebron, Dept Biochem, CIBERehd Inst Carlos III, Barcelona 08035, Spain

[3] Hosp Valle De Hebron, Div Hematol, Barcelona 08035, Spain

关键词: Entecavir;    HBV reactivation;    Rituximab;   

DOI  :  10.1016/j.jhep.2009.07.012

来源: Elsevier

【 摘 要 】

Backgrounds/Aims: Hepatitis B virus (HBV) reactivation following treatment with rituximab has been reported in patients with either HBsAg-positive, or HBsAg-negative and anti-HBc positive infection. Patients with severe reactivation often have a fatal outcome despite treatment with lamivudine. The use of entecavir has not been reported in patients with severe HBV reactivation. Methods: We present a case of a HBsAg-negative patient diagnosed with chronic lymphocytic leukemia who received a chemotherapeutic regimen that included rituximab, who subsequently presented with severe HBV reactivation with ascites, jaundice and coagulopathy and was treated with entecavir. A review of the literature and underlying HBV associated mutations are discussed. Results: Entecavir produced a rapid and sustained suppression of HBV that was associated with rapid clinical improvement without any side effects. Conclusion: Entecavir is an efficacious and safe treatment for severe HBV reactivation. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free